{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:40:55Z","timestamp":1792672855002,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["brainanddevelopment.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain and Development"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.braindev.2026.104605","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:00:26Z","timestamp":1792659626000},"page":"104605","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment-associated factors potentially linked to relapse in pediatric MOG antibody-associated disease: An exploratory case series"],"prefix":"10.1016","volume":"48","author":[{"given":"Shimpei","family":"Matsuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shino","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takato","family":"Akiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayuko","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Ikeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimpei","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunobu","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Tomizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Sakuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.braindev.2026.104605_bb0005","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1212\/NXI.0000000000000089","article-title":"MOG cell-based assay detects non-MS patients with inflammatory neurologic disease","volume":"2","author":"Waters","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.braindev.2026.104605_bb0010","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrneurol.2013.118","article-title":"The spectrum of MOG autoantibody-associated demyelinating diseases","volume":"9","author":"Reindl","year":"2013","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.braindev.2026.104605_bb0015","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1007\/s00415-017-8635-4","article-title":"Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study","volume":"264","author":"Mariotto","year":"2017","journal-title":"J Neurol"},{"key":"10.1016\/j.braindev.2026.104605_bb0020","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1212\/NXI.0000000000000060","article-title":"MOG antibody-associated diseases","volume":"2","author":"Reindl","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.braindev.2026.104605_bb0025","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.braindev.2026.104605_bb0030","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejpn.2020.10.005","article-title":"E.U. Paediatric MOG consortium consensus: part 5 - treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders","volume":"29","author":"Bruijstens","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.braindev.2026.104605_bb0035","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1007\/s00415-018-9122-2","article-title":"Neurological update: MOG antibody disease","volume":"266","author":"Wynford-Thomas","year":"2019","journal-title":"J Neurol"},{"key":"10.1016\/j.braindev.2026.104605_bb0040","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11940-019-0541-x","article-title":"Treatment approaches for MOG-ab-associated demyelination in children","volume":"21","author":"Hacohen","year":"2019","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.braindev.2026.104605_bb0045","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.braindev.2026.104605_bb0050","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","article-title":"Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"75","author":"Hacohen","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.braindev.2026.104605_bb0055","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.braindev.2026.104605_bb0060","article-title":"Early immunotherapy and longer corticosteroid treatment are associated with lower risk of relapsing disease course in pediatric MOGAD","volume":"10","author":"Nosadini","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.braindev.2026.104605_bb0065","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/jnnp-2024-333464","article-title":"Predictors of a relapsing course in myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"96","author":"Virupakshaiah","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.braindev.2026.104605_bb0070","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1136\/jnnp-2024-333463","article-title":"Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse","volume":"95","author":"Trewin","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.braindev.2026.104605_bb0075","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/1352458513484547","article-title":"International pediatric multiple sclerosis study group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions","volume":"19","author":"Krupp","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.braindev.2026.104605_bb0080","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1001\/archopht.1991.01080120057025","article-title":"The clinical profile of optic neuritis. Experience of the optic neuritis treatment trial","volume":"109","year":"1991","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.braindev.2026.104605_bb0085","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1212\/WNL.59.4.499","article-title":"Proposed diagnostic criteria and nosology of acute transverse myelitis","volume":"59","author":"Transverse Myelitis Consortium Working Group","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.braindev.2026.104605_bb0090","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.braindev.2026.104605_bb0095","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.braindev.2026.104605_bb0100","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1093\/brain\/awad122","article-title":"Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids","volume":"146","author":"Matsumoto","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.braindev.2026.104605_bb0105","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1136\/practneurol-2017-001787","article-title":"Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations","volume":"19","author":"Jurynczyk","year":"2019","journal-title":"Pract Neurol"},{"key":"10.1016\/j.braindev.2026.104605_bb0110","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejpn.2020.10.007","article-title":"E.U. Paediatric MOG consortium consensus: part 4 - outcome of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders","volume":"29","author":"Bruijstens","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.braindev.2026.104605_bb0115","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209303","article-title":"Radiologic lag and brain MRI lesion dynamics during attacks in MOG antibody-associated disease","volume":"102","author":"Cacciaguerra","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.braindev.2026.104605_bb0120","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200309","article-title":"A simple score (MOG-AR) to identify individuals at high risk of relapse after MOGAD attack","volume":"11","author":"Xu","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Brain and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760426001063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760426001063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:40:23Z","timestamp":1792669223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0387760426001063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S0387760426001063"],"URL":"https:\/\/doi.org\/10.1016\/j.braindev.2026.104605","relation":{},"ISSN":["0387-7604"],"issn-type":[{"value":"0387-7604","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment-associated factors potentially linked to relapse in pediatric MOG antibody-associated disease: An exploratory case series","name":"articletitle","label":"Article Title"},{"value":"Brain and Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.braindev.2026.104605","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104605"}}